Sean C. Grondin's research while affiliated with Brigham and Women's Hospital and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Malignant pleural mesothelioma (MPM) is a rare tumor that predominantly afflicts men over 50 years of age. Nearly 3000 MPMs are reported annually in the United States with the incidence expected to rise into the new millenium. Over the past 40 years, MPM has been unequivocally linked to asbestos exposure worldwide. Recently, however, a new theory o...
Malignant pleural mesothelioma (MPM) is predominantly a local/regional disease that results in a survival time that ranges from 4 to 12 months without treatment. Single-modality therapy using surgery, chemotherapy, or radiotherapy alone is largely ineffective. The objective of the study was presentation of the use of pleuropneumonectomy in a multim...
Malignant pleural mesothelioma is an aggressive tumor associated with exposure to asbestos. Although this disease is rare, with an annual incidence in the United States of 2,000 to 3,000 cases, a steady rise in cases has been reported. Malignant pleural mesothelioma has a variable clinical presentation and may be difficult to diagnose. Pathological...
This article reviews the preoperative assessment and selection of patients for extrapleural pneumonectomy, the surgical technique, and recent data outlining our experience with multimodality therapy for MPM.
Citations
... Contrast enhancement of sites of previous entry to the chest were not, in themselves, seen as any contraindication to radical treatment, as these were widely excised at surgery. Suitable patients then underwent extra-pleural pneumonectomy (EPP) or radical pleurectomy/decortication (PD) according to established techniques [12,13]. Systematic clearance of ipsilateral mediastinal and internal mammary lymph node groups was performed. ...
... Hitherto rare, MM incidence has been increasing since the second half of the 20th century, a context in which MM has been linked to the indiscriminate use of asbestos over the last century. (2) The true extent of such worldwide MM epidemic is unknown. Currently, the greatest burden of asbestos use concentrates in Brazil, Russia, India, and China. ...
Reference: Malignant pleural mesothelioma: an update
... Extra-pleural pneumonectomy (EPP) is an extensive surgery associated with perioperative morbidity of 60-63% [1,2]. Extrapleural pneumonectomy (EPP) or pleuropneumonectomy for diffuse malignant pleural mesothelioma is a radical surgery which includes en bloc resection of the pleura, lung, ipsilateral hemidiaphragm and anterior pericardium [3]. Cardiac herniation is extremely rare post-operative life-threatening condition associated with mortality rate (50-100%) [4,5]. ...
... Malignant mesothelioma is a malignant tumor that develops on serous surfaces, such as the pleura or peritoneum [7]. The disease progresses rapidly and the subject dies within 4-12 months of its onset with only supportive care [8]. It is known to occur after exposure to a smaller amount of asbestos as compared to larger amounts that trigger lung cancer [9]. ...
